Bioavailability Enhancement CDMO Market Size, Share, Scope Report 2026 to 2035
What is Bioavailability Enhancement CDMO Market Size?
Global Bioavailability Enhancement CDMO Market is estimated to grow with a 10.5% CAGR during the forecast period for 2026 to 2035.
Bioavailability Enhancement CDMO Market Size, Share & Trends Analysis Distribution by Service Type (Development Services, Clinical Manufacturing, Commercial Manufacturing), By Bioavailability Enhancement Technology (Amorphous Solid Dispersion (ASD), Particle Size Reduction, Lipid-Based Formulation, Solubilization & Complexation, Other Enabling Technologies), By Route / Final Dosage Form (Oral Solid Dosage, Oral Liquid & Softgel, Parenteral / Injectable, Other / Emerging Routes) and Segment Forecasts, 2026 to 2035.

Bioavailability enhancement encompasses formulation and drug-delivery technologies designed to improve the solubility, dissolution, absorption, and systemic availability of active pharmaceutical ingredients (APIs). These technologies are particularly important for poorly water-soluble drug molecules, which may exhibit limited dissolution and absorption and therefore require specialized formulation approaches to achieve adequate systemic exposure and therapeutic performance. Bioavailability enhancement strategies are designed to modify the physicochemical and biopharmaceutical properties of drug substances while supporting the development of stable, effective, scalable, and manufacturable drug products.
The technology landscape includes a broad range of formulation and drug-delivery approaches, including amorphous solid dispersions (ASDs), spray-dried dispersions, hot-melt extrusion, micronization, nanomilling, lipid-based formulations, self-emulsifying drug delivery systems (SEDDS), cyclodextrin complexation, and other solubilization and enabling technologies. These approaches can improve dissolution characteristics, enhance drug solubility, facilitate absorption, or otherwise optimize the delivery of challenging APIs. Bioavailability enhancement technologies can be incorporated into multiple dosage forms, including oral tablets, capsules, multiparticulates, softgels, oral liquids, and selected injectable formulations, depending on the characteristics of the drug and the intended therapeutic application.
The Bioavailability Enhancement CDMO Market comprises outsourced contract development and manufacturing services that support the formulation, optimization, scale-up, and manufacturing of drug products requiring enhanced bioavailability. Service capabilities can extend from developability assessment and biopharmaceutics evaluation to formulation screening and development, particle engineering, process optimization, analytical characterization, clinical manufacturing, technology transfer, and GMP-compliant commercial manufacturing. These services enable pharmaceutical and biotechnology companies to access specialized formulation expertise, development infrastructure, manufacturing technologies, and scale-up capabilities across different stages of the drug development lifecycle.
Bioavailability enhancement CDMO services support programs ranging from early formulation development and preclinical studies through clinical development and commercial drug product manufacturing. Service providers may specialize in a particular formulation technology or offer integrated capabilities covering development, clinical manufacturing, and commercial production. The market encompasses global CDMOs and specialized formulation development companies serving pharmaceutical and biotechnology clients with technology-specific or end-to-end bioavailability enhancement capabilities.
The market can be categorized by service type, including development services, clinical manufacturing, and commercial manufacturing; by bioavailability enhancement technology, including amorphous solid dispersions, particle size reduction, lipid-based systems, solubilization and complexation, and other enabling technologies; and by route or final dosage form, including oral solid dosage, oral liquid and softgel, parenteral or injectable, and other emerging routes. The market focuses on revenue generated from third-party bioavailability enhancement development and manufacturing services and excludes revenue associated solely with excipient sales, equipment manufacturing, and unrelated pharmaceutical manufacturing activities.
Competitive Landscape
Which are the Leading Players in the Bioavailability Enhancement CDMO Market?
- Lonza Group AG
- Catalent, Inc.
- Hovione
- Quotient Sciences
- Evonik Industries AG
- Ardena
- Piramal Pharma Solutions
- Adare Pharma Solutions
- Thermo Fisher Scientific Inc. (Patheon)
- Serán Bioscience
- Agno Pharma (Particle Sciences)
- Codis
- Bend Bioscience
- Aenova Group
- Recipharm
- Pace Life Sciences
- Ascendia Pharmaceutical
- WuXi STA (WuXi AppTec)
Market Dynamics
Driver
Increasing Prevalence of Poorly Water-Soluble Drug Candidates and Demand for Advanced Formulation Technologies
The increasing number of poorly water soluble drug candidates in the pharma and biotech development pipeline is a major driver of the bioavailability enhancement CDMO market. A large number of the new small molecule drugs that are developed are going to be poorly water soluble and hence have dissolution issues which in turn will impact on absorption, systemic exposure and efficacy. As a result there is a clear trend for pharma and biotech companies to outsource their formulation development and manufacturing of these types of products to CDMOs that have the specific expertise in bioavailability enhancement. The range of technologies available in this space is broad and includes amorphous solid dispersions (ASDs), spray dried dispersions, hot melt extrusion, nanomilling, micronisation and lipid based systems. The CDMOs in this space offer a full range of services from early stage formulation screening and developability through to process optimisation, clinical manufacture and commercial scale manufacture. The increasing complexity of the drug molecules and the need for specialist formulation expertise and manufacturing infrastructure is further underpinning the role of the bioavailability enhancement CDMO throughout the drug development lifecycle and this is in turn driving market growth.
Restrain/Challenge
Technical Complexity and Scale-Up Challenges in Bioavailability-Enhanced Drug Formulations
The high degree of technical complexity involved in the development and scale-up of bioavailability enhanced drug formulations is a key challenge for the Bioavailability Enhancement CDMO market. Poorly water soluble drug molecules are often very complex in their physicochemical properties and it can be very difficult to identify the right formulation technologies to consistently improve solubility, dissolution, absorption and stability. The more sophisticated the formulation technology (amorphous solid dispersions, spray drying, hot melt extrusion, nanomilling, lipid based systems etc) the more specialised the equipment, the greater the formulation expertise required and the more critical the control of the manufacturing parameters. Scale-up from lab development through to clinical and commercial manufacture can present its own set of problems in terms of physical stability, drug recrystallisation, particle size consistency, process reproducibility and the maintenance of the desired PK profile. There are also the additional hurdles of stringent regulatory requirements, the need for extensive analytical characterisation and the complexity of technology transfer which can all lead to longer development times and higher manufacturing costs. The technical and operational challenges can therefore have a significant impact on the ability to produce efficiently and can present a real challenge for a CDMO looking to deliver a consistently scalable bioavailability enhanced drug product.
Commercial Manufacturing Segment is Expected to Drive the Bioavailability Enhancement CDMO Market
Commercial Manufacturing is expected to be the largest segment in the bioavailability enhancement CDMO market, driven by the rising demand for large scale production of bioavailability enhanced formulations and the increasing trend of pharma and biotech companies outsourcing their speciality manufacturing. This segment covers GMP production of a range of advanced formulations including amorphous solid dispersions, spray dried dispersions, hot melt extruded products and a range of other advanced formulations. The growth of this segment is being supported by the increasing commercialisation of poorly water soluble drug candidates and the need for the associated manufacturing infrastructure, process validation and consistent product quality. The strength of the commercial manufacturing segment is also being underpinned by the nature of the business with long term manufacturing agreements, recurring commercial supply contracts and the inherent technical complexity of scaling up these types of formulations.
Particle Size Reduction Segment is Growing at the Highest Rate in the Bioavailability Enhancement CDMO Market
The particle size reduction segment is set to be the fastest growing in the bioavailability enhancement CDMO market, driven by the growing demand for advanced particle engineering technologies to improve the dissolution and absorption of poorly water soluble drug molecules. Micronisation, nanomilling and nanosuspension are all technologies that are being increasingly utilised in drug development to increase the surface area of the drug particle, improve the dissolution rate and hence the bioavailability of the drug, without any change to the drug molecule itself. Pharma and biotech companies are increasingly turning to CDMOS for particle size optimisation, formulation development, process scale-up and GMP manufacture. There is also a clear trend towards the use of more sophisticated wet media milling, improved nanosuspension stabilisation and more precise particle engineering. This is all expected to drive growth in the segment.
Why North America Led the Bioavailability Enhancement CDMO Market?
North America is projected to be the largest market for the bioavailability enhancement CDMO market, driven by the presence of a large number of established pharma and biotech companies, a mature drug development infrastructure and a huge amount of investment in pharma R&D. The US is the clear leader in the region with the presence of a number of well known CDMOs including Lonza, Catalent, Thermo Fisher Scientific (Patheon), Serán Bioscience and Bend Bioscience who offer a wide range of formulation development and particle engineering capabilities as well as clinical to commercial manufacturing.

The market in the region is being driven by the increasing number of poorly water soluble drug candidates, the growing uptake of amorphous solid dispersions, spray drying, hot melt extrusion and nanomilling technologies and the increasing outsourcing of complex formulation work. The region also benefits from a good number of dedicated manufacturing facilities, a pool of experienced formulation scientists, a well established regulatory environment and continued investment in commercial scale manufacturing capacity.
Key Development
September 2026: Lonza announced plans to expand its US manufacturing footprint with a large-scale commercial spray-drying facility in Bend, Oregon. The investment will strengthen its spray-dried dispersion (SDD) capabilities, supporting clinical and commercial drug development programs. The expansion aims to address growing demand for bioavailability enhancement technologies, particularly for poorly soluble drug molecules, while reinforcing Lonza’s integrated development and manufacturing services.
Bioavailability Enhancement CDMO Market Report Scope:
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 10.5% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Service Type, Bioavailability Enhancement Technology, Route / Final Dosage Form and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia |
| Competitive Landscape | Lonza Group AG, Catalent, Inc., Hovione, Quotient Sciences, Evonik Industries AG, Ardena, Piramal Pharma Solutions, Adare Pharma Solutions, Thermo Fisher Scientific Inc. (Patheon), Serán Bioscience |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentations Bioavailability Enhancement CDMO Market:
Bioavailability Enhancement CDMO Market by Service Type -
- Development Services
- Clinical Manufacturing
- Commercial Manufacturing
Bioavailability Enhancement CDMO Market by Bioavailability Enhancement Technology -
- Amorphous Solid Dispersion (ASD)
- Particle Size Reduction
- Lipid-Based Formulation
- Solubilization & Complexation
- Other Enabling Technologies
Bioavailability Enhancement CDMO Market by Route / Final Dosage Form -
- Oral Solid Dosage
- Oral Liquid & Softgel
- Parenteral / Injectable
- Other / Emerging Routes
Bioavailability Enhancement CDMO Market by Region-
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East and Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Bioavailability Enhancement CDMO Market is estimated to grow with a 10.5% CAGR during the forecast period for 2026 to 2035.
Lonza Group AG, Catalent, Inc., Hovione, Quotient Sciences, Evonik Industries AG, Ardena, Piramal Pharma Solutions, Adare Pharma Solutions, Thermo Fisher Scientific Inc. (Patheon), Serán Bioscience and Others.
Iprodione Market is segmented into Service Type, Bioavailability Enhancement Technology, Route / Final Dosage Form and Other.
North America region is leading the Bioavailability Enhancement CDMO Market.
